Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN1 | Q9GZT9 | 3/20 | 0.39 |
| ▸ | ITGB3 | P05106 | 10/20 | 0.38 |
| ▸ | ITGB1 | P05556 | 10/20 | 0.38 |
| ▸ | ITGAV | P06756 | 10/20 | 0.38 |
| ▸ | ITGA5 | P08648 | 10/20 | 0.38 |
| ▸ | ITGB5 | P18084 | 10/20 | 0.38 |
| ▸ | ITGA2B | P08514 | 7/20 | 0.38 |
| ▸ | CCR1 | P32246 | 2/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | MMP3 | P08254 | 1/20 | 0.34 |
| ▸ | ACACB | O00763 | 1/20 | 0.34 |
| ▸ | ADRB2 | P07550 | 2/20 | 0.33 |
| ▸ | ADRB1 | P08588 | 2/20 | 0.33 |
| ▸ | ADRB3 | P13945 | 2/20 | 0.33 |
| ▸ | EGLN3 | Q9H6Z9 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1772612 | 0.91 | EGLN1 (0.46) | EGLN1ITGB3ITGB1ITGAVITGA5 | |
| SCHEMBL1773530 | 0.90 | EGLN1 (0.41) | EGLN1ITGB3ITGB1ITGAVITGA5 | |
| SCHEMBL1773761 | 0.89 | EGLN1 (0.42) | EGLN1ITGB3ITGB1ITGAVITGA5 | |
| SCHEMBL1773172 | 0.89 | EGLN1 (0.43) | EGLN1ITGB3ITGB1ITGAVITGA5 | |
| SCHEMBL1773441 | 0.88 | EGLN1 (0.50) | EGLN1ITGB3ITGB1ITGAVITGA5 | |
| SCHEMBL12005323 | 0.87 | EGLN1 (0.47) | EGLN1ITGB3ITGB1ITGAVITGA5 | |
| SCHEMBL12006114 | 0.87 | EGLN1 (0.45) | EGLN1ITGB3ITGB1ITGAVITGA5 | |
| SCHEMBL1773089 | 0.85 | ITGB3 (0.40) | ITGB3ITGB1ITGAVITGA5ITGB5 | |
| SCHEMBL1773165 | 0.85 | EGLN1 (0.43) | EGLN1ITGB3ITGB1ITGAVITGA5 | |
| SCHEMBL1773338 | 0.84 | EGLN1 (0.48) | EGLN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110112103-A1 | 5-HYDROXYPYRIMIDINE-4-CARBOXAMIDE COMPOUND | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2011-05-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110112103-A1 | 5-HYDROXYPYRIMIDINE-4-CARBOXAMIDE COMPOUND | EPOR, CBR1, CBR3 | EGLN1 16/4885ITGB3 4005/4885ITGB1 4142/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.